Status:
ACTIVE_NOT_RECRUITING
Radiomics and Molecular Classification in Endometrial Cancer
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Conditions:
Endometrial Cancer
Uterine Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Molecular/genomic profiling is the most accurate method to assess the prognosis of endometrial cancer patients. Interestingly, the adoption of radiomics showed important results, across various oncolo...
Eligibility Criteria
Inclusion
- (i) preoperative endometrial cancer (any histology); (ii) preoperative ultrasonographic examination; (iii) surgical treatment; (iv) age \>= 18 years; (v) signed informed consent for research purposes.
Exclusion
- (i) consent withdraw; (ii) lack of available (tumor) tissue for molecular/genomic profiling.
Key Trial Info
Start Date :
January 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT06963385
Start Date
January 15 2021
End Date
December 31 2026
Last Update
May 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Milan, Italy, 20133